Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabiximols for Spasticity in NMOSD
NCT05974293Phase 2Withdrawn
- Start
- Dec 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabis extract in Neuromyelitis Optica Spectrum Disorder (NMOSD). Planned start Dec 2026; status: withdrawn.
02
Drugs
cannabis extract
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05974293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05974293.